WuXi STA to Purchase Bristol Myers Squibb’s Switzerland Manufacturing Facility

February 2, 2021
Pharmaceutical Technology Editors

WuXi STA will acquire the site’s operations and assets, including the plant, equipment, and workforce.

WuXi STA, a subsidiary of WuXi AppTec, announced on Feb. 2, 2021 that it will purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The facility will be WuXi STA’s first European site.

Under the terms of the agreement, WuXi STA will acquire the site’s operations and assets, including the plant, equipment, and workforce, WuXi STA said in a company press release. The transaction is expected to close by the second quarter of 2021.

“The Couvet site is a world-class facility designed for quality, safety, and efficiency, and we believe WuXi STA will be able to leverage the capacity and capabilities for its own operations as it continues to play a vital role for patients around the world,” said Lou Schmukler, president, Global Product Development and Supply, Bristol Myers Squibb, in the press release. “This is an important step in the ongoing evolution of our manufacturing network to support our product portfolio. Switzerland remains an important strategic location for Bristol Myers Squibb, and we look forward to maintaining a strong presence in the Neuchâtel area.”

“We are pleased to add the Couvet manufacturing facility to our growing global manufacturing site network and look forward to working with the talented team who share our focus on excellence and a patient-centered approach,” added Dr. Minzhang Chen, CEO of WuXi STA, in the press release. “The acquisition will allow WuXi STA to better serve European markets and support our global customers to deliver innovative medicines and treatments to patients around the world.”

Source: WuXi STA